been called 'a less morally authoritative document' than the Declaration of Helsinki, lacking moral principles and guidance in the following areas: Disclosure of conflict of interest Public disclosure of study design Benefit for populations in which research is conducted Reporting of accurate results and publication of negative findings Access to treatment after research has been conducted Restriction of use of placebo in control group where effective alternative treatment is available In the book Bad Pharma, Ben Goldacre mentions these criticisms and notes that the GCP rules "aren't terrible... [they are] more focused on procedures, while Helsinki clearly articulates moral principles". See also Data monitoring committees Directive 2001/20/EC (European Union) Drug development EudraVigilance European Forum for Good Clinical Practice (EFGCP) European Medicines Agency (EMEA) GxP Human experimentation in the United States Institutional review board Inverse benefit law Medical ethics Pharmacovigilance Pharmaceutical company References External links ICH Topic E 6 (R2) Good Clinical Practice (from U.S. Food and Drug Administration) Some Relevant UK Statutory Instruments The Medicines for Human Use (Clinical Trials) Regulations 2004 The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 The Medicines for Human Use (Clinical Trials) Amendment (No.2) Regulations 2006 Clinical research Pharmaceutical industry Good practice